Koshinski Asset Management Inc. Invests $1.86 Million in Exact Sciences Co. (NASDAQ:EXAS)


Share on StockTwits

Koshinski Asset Management Inc. bought a new position in shares of Exact Sciences Co. (NASDAQ:EXAS) in the fourth quarter, Holdings Channel reports. The fund bought 18,205 shares of the medical research company’s stock, valued at approximately $1,858,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. DekaBank Deutsche Girozentrale lifted its holdings in shares of Exact Sciences by 14.9% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 35,461 shares of the medical research company’s stock worth $4,676,000 after buying an additional 4,601 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of Exact Sciences during the fourth quarter worth $320,000. Eaton Vance Management raised its stake in Exact Sciences by 20.6% in the fourth quarter. Eaton Vance Management now owns 292,600 shares of the medical research company’s stock valued at $38,767,000 after purchasing an additional 50,006 shares in the last quarter. Jackson Grant Investment Advisers Inc. acquired a new position in Exact Sciences in the fourth quarter valued at about $53,000. Finally, Norges Bank acquired a new position in Exact Sciences in the fourth quarter valued at about $201,627,000. 90.39% of the stock is owned by institutional investors.

In other news, insider Graham Peter Lidgard sold 11,735 shares of the company’s stock in a transaction that occurred on Friday, March 5th. The stock was sold at an average price of $121.33, for a total transaction of $1,423,807.55. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin T. Conroy sold 16,420 shares of the company’s stock in a transaction that occurred on Wednesday, February 24th. The stock was sold at an average price of $136.30, for a total value of $2,238,046.00. Following the transaction, the chief executive officer now directly owns 826,785 shares in the company, valued at $112,690,795.50. The disclosure for this sale can be found here. Insiders have sold 60,428 shares of company stock worth $8,114,785 over the last ninety days. 1.80% of the stock is owned by insiders.

A number of research analysts recently commented on EXAS shares. Zacks Investment Research downgraded Exact Sciences from a “hold” rating to a “strong sell” rating and set a $123.00 price target for the company. in a research note on Tuesday, March 16th. Truist started coverage on Exact Sciences in a research note on Wednesday, January 27th. They issued a “buy” rating and a $226.00 price target for the company. Robert W. Baird dropped their price target on Exact Sciences from $169.00 to $163.00 and set an “outperform” rating for the company in a research note on Thursday, February 18th. TheStreet downgraded Exact Sciences from a “c” rating to a “d+” rating in a research note on Wednesday, February 24th. Finally, Canaccord Genuity boosted their price target on Exact Sciences from $160.00 to $165.00 and gave the company a “buy” rating in a research note on Tuesday, January 12th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $148.63.

Shares of EXAS opened at $129.18 on Thursday. Exact Sciences Co. has a 52-week low of $61.60 and a 52-week high of $159.54. The company has a debt-to-equity ratio of 0.68, a quick ratio of 6.04 and a current ratio of 6.35. The business’s 50 day moving average price is $132.09 and its two-hundred day moving average price is $127.16. The firm has a market cap of $21.84 billion, a PE ratio of -58.45 and a beta of 1.64.

Exact Sciences (NASDAQ:EXAS) last issued its earnings results on Monday, February 15th. The medical research company reported ($2.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($2.60). Exact Sciences had a negative return on equity of 11.71% and a negative net margin of 25.27%. The firm had revenue of $466.34 million for the quarter, compared to analyst estimates of $465.98 million. Research analysts predict that Exact Sciences Co. will post -1.56 EPS for the current fiscal year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services.

Read More: How can investors invest in the S&P/TSX Index?

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXAS).

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.